Advanced search
Publication Cover
Leukemia & Lymphoma Volume 43, 2002 - Issue 9
Submit an article Journal homepage
384
Views
88
CrossRef citations to date
0
Altmetric
Research Article

The Treatment of Acute Myeloid Leukemia in First Relapse: A Comprehensive Review of the Literature

Lance H. Leopold Department of Clinical Research and Development, Wyeth Research, P.O. Box 42528, Philadelphia, PA 19101, USA
&
Roel Willemze Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
Pages 1715-1727 | Published online: 01 Jul 2009

  • Lowenberg, B., Downing, J.R. and Bunten, A. (1999) "Acute myeloid leukemia". New England Journal of Medicine 341. 1051-1062.
  • Rowe, J.M. (1998) "What is (he best induction regimen for acute myelogcnous. leukemia'.'". Leukemia 12. S16-SI9.
  • Forman, S.J., Nademanee, A.P., O'Donnell, M.R., Fancy, J.L. Snyder, D.S., Farbstcin, M.J., Lazar, C.S., DuBois, N.J. and Blume, K.C. (1985) "High-dose cytosine arabinoside and daunomycin as primary therapy tor adults with acute nonlymphoblastic leukemia: a pilot study". Seminars in Oncology 12. 114-116.
  • Chumplin, C.R. (1989) "Bone marrow transplantation for acute myelogenous leukemia". Recent Advances in Bone Marrow Transplantation: Current Controversies (Lias. New York), pp 95-106.
  • Hiddemann, W., Kern, W., Schoch, C., Fonatsch, C., Heinecke, A., Wormann, B. and Buchner, T. (1999) "Management of acute myeloid leukemia in elderly patients". Journal of Clinical Oncology 17. 3569-3776.
  • Mayer, R.J., Davis, R.B., Schiffer, C.A., Berg, D.T., Powell, B.L., Schulman, P., Omura, G.A., Moore, J.O., Mclnlyre, O.R. and Frei, E. (1994} "3rd Intensive postrcmission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B". New England Journal of Medicine 131. 896-903.
  • Burnett, A.K., Coldstone, A.H., Stevens, R.M., Hann, I.M., Rees, J.K., Gray, R.G. and Whealley, K. (1998) "Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AMI, 10 trial. UK Medical Research Council Adult and Children's leukaemia Working Parties". Lancer 351.700-708.
  • Ziltoun, R.A., Mandelli, K. Willemze, R., de Witte, T., Labar, B., Resegotti, I., Leoni, F., Damasio, E., Visani, G., Papa, G., Caronia, R, Hayat, M., Stryckmans, P., Rotoli, B., Leoni, P., Peetermans, M.E., Dardanne, M., Vegna, M.l., Petti, M.C., Solbu, G. and Sueiu, S. (1995) "Autologous. or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelugenous leukemia. European Organisation for Research and Treatment of Cancer (EORTC) and the Gruppu ltaliano Malattie Emalologichc Maligne dell' Adulto (GlMEMA) Leukemia Cooperative Groups". New England Journal of Medicine 332.217-223.
  • Kuntarjian, H.M., Keating, M.J., Wallers, R.S., McCredic, K.B. ami Freireich, R.J. (1988) "The characteristics and outcome of putients with late relapse acute myelogenous leukemia". Journal of Clinical Oncology 6. 232-238.
  • Kern, W., Schoch, C., Haferlach, T., Braess, J., Unterhalt, M., Woermanu, B., Buechner, T. and Hiddemann, W. (1998) ".Significance of cytogenetic abnormalities in a multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia". Blood 92,78A-79A.
  • Kent, W., Schoch, C. Haferlach, T., Braess, J., Unterhalt, M., Wormann, B., Buchner, T. und Hiddemann, W. (2000) "Multivariate analysis of prognostic factors in patients with) refractory and relapsed acute myeloid leukemia undergoing sequential highdose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities". Leukemia 14. 226-231.
  • Schiller, G.J. (1998) 'Treatment of resistant disease", leukemia 12.S20-S24.
  • Rees, J.K., Gray, R.G., Swirsky, D. and Hayhoe, F.G. (1986) "Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial". lancet 2. 1236-1241.
  • Keating, M.J., Kantarjian, H., Smith, T.L., Estey, E., Walters, R., Andersson, B., Beran, M., McCredie, K.B. and Freireich, E.J. (1989) "Response to salvage therapy and survival after relapse in acute myelogunous leukemia". Journal of Clinical oncology 7. 1071-1080.
  • Thalhammer, F., Geisoler, K., Jager, U., Kyrle, P.A., Pabinger, I., Mitterbauer, M., Oeisslor, H., Knob), P., Lazczika, K., Schneider, B., Haas, O.A. and Lechner, K. (1996) "Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study", Annals of Hematology 72. 216-222.
  • Hiddemann, W., Martin, W.R., Sauerland, C.M., Heinecke, A. and Buchner, T. (1990) "Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based at the results of retreatment by thioguanine. cyiosine arabinoside and daunorubicin (TAD 9) in ISO patients with relapse after standardized tint line therapy". Leukemia 4. 184-188.
  • Davis, C.L., Rohatiner, A.Z., Lim, J., Whelan, J.S., Oza, A.M., Amess, J., Love, S., Stead, E. and Lister, T.A. (1993) The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period". British Journal of Haematalagy 83.404-411.
  • Angelov, L., Brundwein, J.M., Baker, M.A., Scou, J.G., Sutton, D.M. and kealing, A. (1991) -Result of Therapy for Acute Myeloid Leukemia in First Relapse". Leukemia and Lymphtmta 6. 15-24.
  • Peterson, B.A. and Bluomtield, C.D. (1981) "Re-induction of complete remissions in adults with acute non-lymphocyiic leukemia". Leakemia Research 5. 81 -88.
  • MacCallum, P.K., Davis, C.L., Rohatincr, A.Z., Lim, J., Gupta, R.K., Whelan, J.S., Price, C.C., Evans, M.L., Amess, J.A., Lcahy, M., Johnson, P.W.M., Oza, A.M. and Lister, T.A. (1993) "Mitoxantrone and cyiosine arabinoside at treatment for acute myelogenouss leukemia (AML) at lust recurrence". Leukemia 7. 1496-1499.
  • Letendre, L., Kiely. J-M. and Hoagland, H.C. (1984) "Reinduction chemotherapy for acute nanlymphocytic leukemia", Maya Clinic Proceedings 59.618-621.
  • Rassam, S.M., Turker, A., Powles, R.L., Smith, A.C., Newland, A.C., Erskine, J.G., Pearce, R.M. and Goldstone, A.H. (1993) "ldarubicin for remission induction of acute myeloid leukemia: United Kingdom multicenter experience". Seminars in Oncology 20.13-19.
  • Welhom, J.L,. Kopecky, K.J., Meyers, F.J., Veith, R., Shurafa, M., Doroshow, J.H., Balcerzak, S.P. and Appeelbaum, F.R. (1995) "Carboplatin infusion in relapsed and refractory acute mycloid leukemia--a Southwest Oncology Group trial", leukemia 9. 1126-1129.
  • Harouuseau, J.L., Hurteloup, P., Reiffers, J., Rigal-Huguet, F., Hayat, M., Dufour, P., c Prise, P.Y., Monconduit, M., Jaubert. 1. and Carcassonne, Y. (1987) "ldarubicin in the treatment of relapsed or refractory acute myeloid leukemia", Cancer Treatment Reports 71.991 -992.
  • Archimbaud, E., Thomas, X., Leblond, V., Michallet, M., Fenaux, P., Cordonnier, C., Dreyfus, F., Troussard, X., Jaubert, J., Travade, P., Trancy, J., Assouline, D. and Fiere, D. (1995) Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide. mituxamronc and cytarabine-86 trial". Journal of Clinical Oncology 13. 11-18.
  • Vignetti, M., Orsini, E., Petti, M.C., Moleti, M.L., Andrizzt, C. Pinto, R.M., Amadori, S. and Meloni, G. (1996) "Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single-centre experience". Annula of Oncology 7.933 938.
  • Carella, A.M., Curlier, P., Pungolino, E., Rescgotii, I., Liso, V., Stasi.R.,Momillo.M.,Iacopino,P., Mirto.S., Pagano.L.,Leoni,F., Martelli, F.M., Di Ruimondo, F., Porcellini, A., de Riu, L., Nosari, A.M., Cimino, R., Damasio, E., Miraglia, E., Fioritoni, G., Ricciuuti, F., Carotenuto, M., Longinontti, M., Defazio, D., Fazi, P. and Mandelli, F. (1993) "Idaruhicin in combination with intermediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. The GIMEMA Cooperative Group", Leukemia 7. 196-199.
  • Harousseau, J.L., Reiffers, J., Hurteloup, P., Milpicd, N., Guy, H., Rigal-Huguet, F., Facon, T., Dulour, P. and itruh, N. (1989) "Treatment of relapsed acute myeloid leukemia with idambicin and intermediate-dose cytarabine". Journal of Clinical Oncology 7.45-49.
  • Peters, W.G., Willemze, R. and Colly, L.P. (1988) "Results of induction and cuasolidation treatment with intermediate and highdose cylosine arabinoside and m-Amsa of patients with poor-risk acute myclogenous leukaemia", European Journal of Haematology 40. 198-204.
  • Briuv Babapulle, F., Catovsky, D., Newland, A.C., Goldman, J.M. and Gallon, D.A. (1987) "Treatment of acute myeloid leukemia with intermediate-dose cytosine arabinoside and mitoxamrone". Seminars in Oncology 14. 51-52.
  • Estey, E., Plunkett, W., Gandhi, V. Rios, M.B., Kantarjian, H. and Keating, M.J. (1993) "Hudarahine and arabinosyletosine therapy of refractory and relapsed acute myclogenous leukemia", Leukemia and Lymohoma 9, 343-350.
  • Jehn, U. and Hcenemann, V. (1990) "Iniermediatc-dose Aru-C/mAMSA for remission induction and high-dose Ara-C/m-AMS A for intensive consolidation in relapsed and refractory adult acute inyelogeneous leukemia". Hannarologic and Bluttransfusion 33. 333.338.
  • Pavlovsky, S., Fernandez, I., Palau, V., Santarelli, M.T., De Bellis, R., Ruiz-Arguelles, G., Brandalise, S. and Jimenez-Fonseca, E. (1991 ) "Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia". Aimais of Oncology 2.441 -442.
  • Komblau, S.M., Kantarjian, H., O'Brien, S., Andreeff, M., Koller. CA., Beran, M., Reeling, M. and Estey, B. (1998) "CECAcyclophosphamidc. cloposide. carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myclogcnous leukemia", leukemia anil Lymphoma 28. 371 - 375.
  • Ho, A.D., Lipp, T., Ehninger, G., Illiger, H.J., Meyer, P., Freund, M. and Hunstein, W. (1988) "Combination of mitoxantrone and etopositk in refractory acute myelogenous leukemia-an active and well-tolerated regimen". Journal of Clinical Oncology 6, 213-217.
  • Harousscau, J.L., Milpied, N., Briere, J., Desablens, B. and Ghandour, C. (1990) "Mitnxuntrone and intermediate-dose cytarabinc in relapsed or refractory acute myeloblastic leemia". Nouvelle Reoute Francaise D' Hematolagie 32. 227-230.
  • Kern, W., AuI, C., Maschmceyer, G.,., Schonrock-Nabulsi, R., Ludwig, W.D., Banhulomaus, A., Bettelheim, P., Wormann, B., Buchner, T. and Hiddemann, W. (1998) "Superiority of high-dose over intermediate-dose cytosine arahinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an ageadjusted prospective randomized comparison", Leukemia 12. 1049-1055.
  • Vogler, W.R., McCuriey, D.L., Stagg, M., Banolucci, A.A., Moore, J., Martelo, O. and Oimira, G. A. (1994) "A phase III trial of highdose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial". Leukemia 8. 1847-1853.
  • Thomas, X., Penaux, P., Dombrei, H., Delair, S., Dreytus, P., Tilly, H., Vckhoff, A., Cony-Makhoul, P., Ublond, V., Troussard, X., Cordonnier, C., de Revel, T., Simon, M., Nicolini, F., Stoppa, A.M., Janvier, M., Bordessoulke, D., Rousselot, P., Ffrench, M., Marie, J.R and Archimbaud, E. (1999) Gramutocyte-macrophage colony-stimulating factor (GM-CSF) to increase eflicacy of intcnsivi- sequential chemotherapy with eroposide. mitoxaninmc and cyiarabine (EMA) in previously treated acute myeloid leukemia: a multicenterr randomized placebo-controlled trial (EMA9I Trial)". leukemia 13. 1214-1220.
  • Ohno, R., Naoc, T., Kanamani, A., Yoshida, M., Hiraoka, A., Kobayasht, T., Ueda, T., Minamt, S., Morlshima, Y., Saito, V., Furusawa, S., lmai, K, Takemoto, Y., Miura, Y., Teshima, H. and Hamajima, N. (1994) "A double-blind controlled study of granulocytc colony-stimulating factor startedtwo days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group". Blood 83.2086-2092.
  • Ferrara, F., MeIiIIo, L., Moniillu, M., Leoni, F., Pinto, A., Mele, G. and Mirto, S. 1(999) "Fludarabine. cytarabine. and G-CSF (Fl. AG) for the treatment of acute myeioid leukemia relapsing after autologous stem cell transplantation". Annals of Henuaalogy 78. 380-384.
  • Saito, K., Nakamura, Y., Aoyagi, M., Waga, K., Yamamoto, K., Aoyagi, A., [noue, P., Nakamura, Y., Arai, Y., Tadukoro, J., Handa, T., Tsurumi, S., Arai, H., Kawagoe, Y., Gunnji, H., Kitsiikawa, Y. Takahashi, W. and Furusawa, S. (2000) 'Low-dose cytarabine and aclaruhicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AMD and previously untreated elderly patients with AML. secondary AML. and refractory anemia with excess blasts in transformation". International Journal of Hemaloiogy 71. 238-244.
  • Sternberg, D.W., Aird, W., Neuberg, D., Thompson, L., MacNeill, K., Amrein. l', und Shulman, L.N. (2000) 'Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantronc and intermediate-dose cytarabine: a pharmacologically based regimen". Cancer 88, 2037-2141.
  • Advani, R., Saha, H.L Tallman, M.S., Rowe, J.M., Wiemik, P.H., Ramek, J., Dugun, K., Lum, B., Villena, J., Davis, B., paietta, E. lichman, M., Sikic, B.I. and Greenberg. p.L. 11999) 'Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodarr. Blood 93.787-795.
  • Amadori, S., Arcese, W., Isacchi, C., Meloni, C., Petti, M.C., Monarca, B., Testi, A.M. and Mandelli. R (1991) "Mitoxantrone. etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia". Journal of Clinical Oncology 9,1210-1214.
  • Amadori, S., Tribatio, M., Pacilli, L., De Laurentis, C. Papa, G. and Mandclli, F. (1980) "Sequential combination of melhotrexaie and 1.-asusnaraginase in the treatment of refractory acute leukemia". Cancer Treatment Reporta 64, 939-942.
  • Archimbaud, E. Anglaret, B.,Thomas, X., Devaux, Y., Ffrench, M., Sebban, C. Troncy, J. and Here, D. (1992) "Continuous-infusion daunorubicin and carboplatin for high-risk acute myeloid leukemia in the elderly". Leukteia 6,776-779.
  • Archimbaud, E. Leblond, V. Michallet, M., Cordonnier, C., Fenaux, P., Travade, P., Dreyfus, F., Jaubert, J., Devaux, Y. ami Fiere, D. (1991) 'Intensive sequential chemotherapy with mitoxamrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia". Blood 77. 1894-1900.
  • Arlin, Z.A., Silver, R., Cassilcth, P., Armentrout, S., Gams, R., Daghestani, A., Coleman, M., Schoch, I. and Dukart, G. (1985) "Phase I-II trial of mitoxantrone in acute leukemia". Cancer Treatment Reports 69. 61 -64.
  • Bassan, R., Lerede, T., BuelIi, M., Borleri, G., Bellavita, P., Rambaldi, A. ami Barhui, T. (1998) "A new combination of carboplatin. high-dose cytarabine and cross-over mitoxantrone or idanibicin for refractory and relapsed acute myeloid leukemia". Haemalologica 83.422-427.
  • Bennett, J.M., Lymann, G.H., Cassileth, P.A., Click, J.H. and Okon, M.M. (1984) "A phase Il trial of VP 16-213 in adults with refractory acute myeloid leukemia. An Eastern Cooperative Oncology Group study". American Journal of Clinical Oncology 7.471-473.
  • Bergmann, L., Heil, G., Kolbc, K., Lengfelder, E., Puzicha, E., Martin, R. Lohmcyer, J., Mitrou, P.S. and Hocker, D. (1995) "Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia". Leukemia ami Lymphoma 16. 271-279.
  • Bezwoda, W.R., Bemasconi, C. Hutchinson, R.M.,Wintield, D.A., de Bock, R. and Mandelli, F. (1990) "Mitoxantrone for refractory and relapsed acute leukemia". Cancer.66 4I8-422.
  • Capizzi, R.L., Poole, M., Cooper, M.R., Richards, F.D., Stuart. J,J., Jackson. Jr., D.V. White, D.R., Spurr, C.L., Hopkins, J.O., Muss, H.B., Rudnick, S.A., Wells, R., Gabriel, D. and Ross, D. (1984) 'Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase". Blood 63,694-700.
  • Capizzi, R.L., Davis, R., Powell, B., Cuttner, J., Ellison, R.R., Cooper, M.R., Dillmun, R., Major, W.B., Dupre, E. and Mclnlyre, O.R. (1988) "Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelngenous leukemia-a Cancer and Leukemia Group B Study". Journal of Clinical Oncology 6. 499-508.
  • Carella, A.M., Samini, G., Martinengo, M., Giordano, D., Nati, S., Congiu, A., Cerri, R., Risso, M., Damasio, E., Rossi, E., Vimercati, R., Pacciarini, M.A. and Mannonl, A.M. (1985) "4-Demethoxydaunorubicin (idanibicin) in refractory or relapsed acute leukemias. A pilot study". Cancer SS. 1452-1454.
  • Daghesuni, A.N., Arlin, Z.A., Lcyland-Jones, B., Gee, T.S., Kerapin, S.J., Mertelimann, R., Budman, D., Schulman, P., Baraiz, R., Williams, L., Clarkson, B.D. and Young, C.W. (1985) "Phase I and O clinical and pharmacological study of 4demethoxydaunorubicin (idanibicin) in adult patients with acute leukemia", Cancer Research 45, 1408-1412.
  • Dekker, A.W., Nieuwenhuis, H.K. and Verdoock, L.F. (1990) "Intermediate-dose cytosine arabinoside and amsacrinc. An effective regimen with low toxicity in refractory acute nonlymphocvtic leukemia". Cancer 65.1891 -1894.
  • Dutcher, J.P., Leong, T., Makary, A.Z., Bennett, J., Frontiera, M., Miller, H. and Wiernik, P.H. (1995) "A phase Il study of menogaril (7R-0-methylnogaroI) in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group". Leukemia 9. 1638- 1642.
  • Esiey, E.H., Keatingj;. MJ., McCrcdic, K.B., Bodey, G.P. and Freircich, E.J. (1983) "Phase H trial of mitoxanuone in refractory acute leukemia". Cancer Treatment Reports 67. 389-390.
  • Evans, C. Winkelstein, A., Rosenfeld, C.S., Zeigler, Z.R. and Shadduck, R.K. (1990) "High-dose cytosine arabinoside and L-asparaginaxe therapy for poor-risk adult acute nonlymphocyiic leukemia. A retrospective study". Cancer 65. 2624-2630.
  • Fiere, D., Campos, U Van, H.V., Guyotat, D., Archimbaud, E., Extra, J.M., Coiffice, B., Viala, J.J., Bryon, P.A., Milan, J.J. and Ritouses, D. (1986) "Intensive timed chemotherapy protocol for 37 resistant or relapsing acute mycloid leukemias*', Cancer Treatment Reports 70,285-286.
  • Freund, M., Ciller, S., Hinrichs, R. Baars, A., Mean, J., Korfer, A., Link, H. and Poliwoda, H. (1999) "Five-day 4'-(9-acridinylaminojinethanesulphon-rn-anisidide and intermediate-dose cyiosine arabinoside in high-risk relapsing or refractory acute myeluid leukemia".Journal of Cancer Research Oncology 117. 489-492.
  • Gore, M., Powles, R., Lakhani, A., Milan, S., Maitland.J., Goss, G., Nandi. A, Perren, T., Forgeson, G., Treleaven, J., Zuiable, A. and Pana, F. (1989) "Treatment of relapsed and refractory acute leukaemia with high-dose cyiosine arabinoside and etoposide". Cancer Cheauaherapy and Phamuicalogy 23.373-376.
  • Herzig, R.H., WoIfT, S.N., Lazarus, H.M., Phillips, G.L., Karanes, C. and Herzig, G.P. (1983) "High-dose cytosine arabinoside therapy for refractory leukemia". Blood 62. 361 -369.
  • Herzig, R.H., Lazarus, K.M., Wolff, S.N., Phillips, G.L and Herzig, G.P. (198S) "High-dose cytosine arabinoside therapy with and without anthracyclinc antibiotics for remission reinduction of acute nonlymphoblaMic leukemia". Journal of Clinical Oncology 3,992-997.
  • Hiddemann, W., Kreuizmann, H., Straif, K., Ludwig, W.D., Mittelsmann, R., Dtmhuijsen-Ant, R., Lengfelder, E., Arlin, Z. and Buchner, T. (1987) "High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia". Blood 69. 744-749.
  • Hiddemann. W1. AuI, C. Maschmeyer, G., Schonruck-Nabulsi, R., Ludwig, W.D., Bartholomaus, A., Beitelheim, P., Becker, K., Balleisen, L., Lathan, B., Kuppler, H., Gruneisen, T., DonhuijsenAnt, R., Reichte, A. and Buchner, T. (1991) "High-dose versus intermediate-dose cytarabine combined with mitoxantrone for the treatment of relapsed and refractory acute mycloid leukemia: results of an age-adjusted randomized comparison". Seminars in Hemaiology 28. 35-38.
  • Hines, J.D., Oken, M.M., Mazza, J.J., Keller, A.M., Streeter, R.R. and Click, J.H. (1984) "High-dose cyiosine arabinoside and m-AMSA is effeciive therapy in relapsed acute nonlymphocytic leukemia". Journal of Clinical Oncriogy 2.545-549.
  • Huhmunn, I.M., Watzke, H.H., Gcissler, K., Gmlinger, H., Jager, U., Knobl, P., Pabinger. !., Korninger, L., Mannhalter, C., Minerbauer, G., Schwarzingce, I., Kalhs, P., Haas, O.A. and Lechncr, K. (1996) "FLAG (fludarabine, cytosine arabinoside, G-CSF) Tor refractory and relapsed acute myeloid leukemia". Annuls of Hrmtitology 73.265-271.
  • Jehn, U., Heinemann, V. und Wilmanns, W. (1989) "lmennedituedose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia IAML)". Aniicancer Research'), 119-124.
  • Jensen, M.K., Johansen, P. and Stemoit, J. (1994) "Salvage therapy with low-dose cytosine arabiooside in refractory or relapsed acute non-lymphocytic leukaemia: a report on 25 patients". European Journal of Haenutologyf, 52. 236-239.
  • Kantarjian, H.M., Estey, E.H., plunkett, W., Keaiing, M.J., Walters, R.S., lacoboni, S., McCredie, K.B. and Freireich, E.J. (1986) "Phase 1-II clinical and pharmacologie studies of highdose cyiosine arabinoside in refractory leukemia". American Journal of Medicine 81. 387-394.
  • Karanes, C., Kupecky, K.J., Head, D.R., Grever, M.R., Hyncs, H.E. Kraut, E.H., Vial, R.H., Lichtin, A., Nand, S., Samlowski, W.E. and Appelbaum, F.R. (1999) "A phase III comparison of high dose ARA-C (HIDAC) versus. HIDAC plus milnxantrone in lhc treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study". Leukemia Research 23. 787-794.
  • Keskin, A., Tombuloglu, M., Atarner, M.A. and Buyukkececi, F. (1994) "Miloxantronee and standard dose cyitosinearabinoside therapy in refractory or relapsed acute leukemia". Ai-ta Harmatologica 92. 14-17.
  • Kornblau, S.M., Gandhi, V., Andrceff, H.M., Benin, M., Kamarjian, H.M., Koller, C.A., O'Brien, S., Plunkett, W. said Estcy, E. (1996) "Clinical and laboratory studies of 2-chtorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults", leukemia 10,1563 -1569).
  • Larson, R.A., Duly, K.M., Choi, K.E., Han, D.S. and Sinkule, J.A. (1987) "A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocy tic leukemia". Journal of Clinical Oncology 5. 391-397.
  • Larson, R.A., Day, R.S., Azamia, N., Benneti, J.M., Browman, G. Goldberg, J., Gollieb, A., Granwald, H., Miller, K., Raza, A., Vogler, R., Winton, E. and Preisler, H.D. (1992) The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergmup study". British Journal of Haematology 82, 337-346.
  • Latagliata, R., Petti, M.C., Spirit!, M.A., Meloni, G., Sgadari, C., Torromc, C, Vegna, M.L. and Mandelli, F. (1990) "High doses of ara-C and m-AMSA in the treatment of refractory acute non lymphocytic leukemia". Haematologica 75.249-251.
  • Lee, E.J., George, S.L., Amrein, P.C. Paciucci, P.A., Allen, S.L. and Schiffer, C.A. (I998) "An evaluation of combinations of diaztquone. ctopnside: and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8723. a randomized phase Ii study conducted by Cancer and Leukemia Group B". Leukemia 12. 139-143.
  • Leone.G.,Pagano.L.,Marra,R.,Landolf.l.,Storti.S., Mango, G., Alfano, G. and D'Onofrio, G. (1987) "Combination of 6-mercaptopurine. vincrislinc, methotrexale, mid prednisone in resistant or relapsed acute nonlymphoid leukemia". Cancer Treatment Reports 71.751-753.
  • Leyden, M., Munoharan, A., Boyd, A., Cheng, Z.M. and Sullivan, J. (1984) "Low dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction". British Journal of Haematalogy 57, 301 -307.
  • Link, H., Freund, M., Diedrich, H., Wilke, H., Austein, J., Henkc, M., Wandt H., Fackler-Schwalbc, E., Schlimok.G., Hotfmann, R., Calavrezos, A. and Poliwoda, H. (1990) Miiuxantnine. cytosine arabinoside. and VP-16 in 36 pateints with relapsed and refractory acute myeloid leukemia". Hamatlogic andl Bluttranfusionn 33. 322-325.
  • Maraninchi, D., Vey, N., Vienv P., Stoppa, A.M., Archimbaud, E., Altai, M., Baumc, D., Bouabdallaia, R., De.meoq, F., Fleury. i, Michallet, M., Olive, D., Reiffen, J., Sainly, D., Tubilio, A., Tiberghien, P., Brandely, M., Hercend, T. and Biaise, D. (1998) "A phase II sludy of imerleukin-2 in 49 patients with relapsed or refractory acute leukemia". Leukemia and Lymphoma 31. 343-349.
  • Martial R.E., Catovsky, D., Goldman, J.M., Galion, D.A., Newland, A.C., Slocombe, G. and Hegde, U. (1985) "Mitoxantrone and high-dose cytarabine in adult acute myeloid leukaemia". lancet l, 1384.
  • Martial, P., Ghilain, J.M., Ferrant, A., Doyen, C. Delannoy, A., Chatelain, C., Bosly, A., Michaux, J.L. and Sokul, G. (1990) "High-dose cytosine arabinoside and amsacrine or miloxantrunc in relapsed and refractory acute myeloid leukaemia: a prospective randomized study", European Journal of Haemaitalogy 45. 164-167.
  • Murtino, R., Brunei. 5., Sureda, A., Matcu, R., Altes, A. and Domingo-Albos, A. (1993) "Treatment of refractory and relapsed adult acute leukemia using a uniform chemotherapy protocol". Leukemia ana lymphama II. 393- 398.
  • Menu, J., Powles, R., Singhal, S., llorton, C., Hamblin, M., Zotans, A., Saso, R., Prendiville, J., Glynne, P., Allford, S., Mackay, H. and Treleaven, J. (1996) "ldarubicin. high dose cylarabine. and etoposide for induction of remission in acute leukemia". Seminars in Hematology 33. 18-23.
  • Montillo, M., Mino, S., Petti, M.C., Lalagliata, R., Magriit S., Pinto, A., Zagonel, V. MeIe, G., Tedeschi, A. and Ferrant, F. (1998) "Flndarahine. cytarabine. and G-CSF (FLAG) for the treatment of poor risk acule mycloid leukemia". American Journal of Hematology58. 105-109.
  • Nokex, T.J., Johnson, S., Harvey. D and Goldutone, AH (1997) "FLAG is a useful regimen for pour prognosis adult myeioid leukaemias and myelodysplastic syndromes". Leukemia and Lymphoma 27. 93-101.
  • O'Brien, S., Kantarjian, H., Estey, E. Kolter, C., Heran, M., McCredie, K. and Keating, M. (1991) "Mitoxamrone and highdose etoposide for patients with relapsed or refractory acute leukemia". Cancer 68,691 -694.
  • Paciueci, P.A., Ohnuma, T., Cuttner, J., Silver, R.T. and Holland, J.F. (1983) "Mttoxanirone in patients with acute leukemia in relapse". Cancer Reaserch 43. 3919-3922.
  • Paciucei, P.A., Cullner, J. and Holland. i.V. (1990) "Sequential intermediate-dose cytosine arahinaside and mitoxantrone for patients with relapsed and refractory acute myclocytic leukemia". American Journal of Hemtology 35. 22-25.
  • Parker, J.E., Pagliuca, A., Mijovic, A., Cullis, J.O., Ceepulkowski, B., Rassam, S.M., Samaratunga, I.R., Grace, R., Cover, P.A. and Mufti, G.J. (1997) "Fludarabine, cytarabine. G-CSF and idarubicin (FlAG-IDA) for the treatment of poor-risk royelodysplasttc syndromes and acute mycloid leukaemia". British Journal of Haematology 99. 939-944.
  • Pascarella, A., Marrani, C. Leuni, F., Ctolli, S., Nozzoli, C. Capurole, R., Salti, F. and Rossi Ferrini, P. (1995) "Low-dose cylosine arabinoside in patients with acute myeloid leukemia not eligible for standard chemotherapy". leukemia and lymphama 18, 465-469.
  • Peterson, B.A., Bloomlield, C.D., Bosl, G.J., Gibbs, G. and Malloy, M. (1980) "Intensive five-drug combination chemotherapy for adult acute non-lymphocytic leukemia". Cancer 46. 663-668.
  • Preister, H.D., Epstein, J., Barcos, M., Priorc, R., Raza, A., Browman, O.P., Vogler, R., Winton, E., Grunwakl, H., Rai, K., Brennan, J., Bennert, S., Goldberg, J., Gontich, A., Chervenick, P., Joyce, R., Miller, K., Larson, R., D'Arrigo, P., Dueblin, T., Stein, M., Bloom, M., Steele, R. and Lee, H. (1984) "Prediction of response of acute nonlymphocyric leukaemia to therapy with high dose cytosine arabinoside. British Journal of Haematolagy 58, 19-32.
  • Puntous, M., Lacumbe, F., Dumain, P., Marit, G., Cony-MakhnuI, P., Belloc, F., Boiron, J.M., Laurent, G., Bernard, P. and Reiffers, J. (1993) "Treatment of relapsed acute mycloid leukemia using GMCSF beforr intensive chemotherapy".LeukemiaLand lymphma. 95-102.
  • Recce, D.E., Elmongy, M.B., Barnen, M.J., Klingemann, H.G., Shepherd, J.D. and Phillips, G.L. (1993) "Chcmotherapy with highdose cytosine arabinoside and miioxamrone for poor-prognosis myeloid leukemias". Cancer Investigation 11. 509-516.
  • Rowe, J.M., Chang, A.Y. and Benneu, J.M. 1988) "Aclecinomycin A and etoposide (VP-16-213) an effective regimen in previously treated patients with refractory acute myelogenous leukemia". Blood 71. 992-996.
  • Rowe, J.M., Mazza, JJ., Mines, J.O., Cassilcth, P.A., Oken, M.M., Benncil, J.M. and Andersen, J. (1991)) "Mitoxantrone and euiposide in patients with relapsed and refractory acute norilymphocytic leukemia". Haniatolagie und Blutiransfusion 33, 326-329.
  • Sauler, C. Fehr, J., Frick, P., Gaumerr, J., Honegger, H. and Martz, G. (1982) "Acute myelogcnous leukemia: successful treatmem of relapse with cytosine arabinoside. VP 16-213. vintristine and vinblastine(A-triple-V)" European Journal of Cancer and clinical Oncologuy 18.73.1-737.
  • Schiller, P., Davis, R.Lee Elberton J. and staszweski.H. Nacint, F. (1996) "High-dose cytarabine and recombinant human granuiotyie colony-stimulating factor for the treatment of resistant acute myclogenous leukemia". Leukemia and Lymphaaia 20. 427-434.
  • Schulman, P., Davis, R., Lee, E., Ellcrton, J. and Stazweski, H. (1987) "Phase Il study of continuous-infusion diaziquoon in relapsed/refracluty acute nonlymphocytic leukemia'*. Cancer Treatment Report 71. 755-757.
  • Schwanz, R.S., Mackintosh, F.R., Halpern, J., Schrier, S.L. and Greenbceg, P.L. (1984)"Multivariatc analysis of factors associated with outcome of treatment for adults, with acute myclogeitou* leukemia". Cancer 54, 1672-1681.
  • Seiler, K., Feldnian, E.J., Holicka, H.D., Traganos K. Danynkiewicz, Z., Lake, D. and Ahmed, T. (1997) "Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia". Journal of Clinical Oncology 15. 44-51.
  • Sinils, P., Schools, L., de Pauw, B.H., de Wine, T., Holdrinet, R.S., Janssen. JT. and Haanen, C. (1987) "Prognostic factors in adult patients with acute leukemia at first relapse", Cancer 59. 1631-1634.
  • Spadea.A., Pelti,M.C.,Fazi.P., Vegna,M.L., Arcese, W., Avvisati, G., Aloe Spirit!, M.A., Latagliata, R., Meloni, G., Tesli, A.M., Amadori, S. and Mandelli, F. (1993) "Mitoxanirone. etoposide and intermediate-dose Ara-C (MEC): an effective regimen Tor poor risk acute myeloid leukemia". Leukemia 7,549-552.
  • Steinmetz, N.T., Schulz., A., Slaib, P., Scheid. C, Glasmacher, A., Neufang, A., Franklin, J., Tesch, H., Diebl, V. and Dias Wickramunayakc, P. (I999) "Phase-II trial of idarubicin, fludarabine., cytosine arabinoside. and filgrastin (Ida-FLAG) for treatment of refractory, relapsed, and secondary AML". Annuls of Hematolgyy 78, 418-425.
  • Tallman, M.S., Lev, S., Sikic, B.J., Paietta, E., Wiemik, P.M., Bennet, J.M. and Rowe, J.M. 11999) "Mitnxantrone. etoposide. and cytarabine plus cyclosonrine fur patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study". Cancer 85. 358-367.
  • Uhlman, D.L., Bloomfield, C.D., Hurd, D.O. and Petersxon. 8.A. (1990) "Prognostic factors al relapse for adults with acute myeloid leukemia1". American Journal of Hematology 33. 110-116.
  • Vahdat, L., Wong, E.T., Wile, M.J., Rosenblum, M., Foley, K.M. and Wanell. Jr., K.P. (1994) "Therapeutic and neurotoxic effects of 2-chloradeoxyadenosine in adults with acute myeloid leukemia". Blood 84. 3429-3434.
  • Van Den Neste E., Martial, P., Mineur, P., Delannoy, A., Doyen, C., Zenebergh, A., Michaux. i.L. and Ferrant, A. (1998) "2-Chtorodcoxyadenoxine with or without daunorubicin in relapsed or refractory acute myeloid leukemia". Annals of Hemathoogy 76. 19-23.
  • Visani, G., Tosi, P., Zinzuni, P.L., Manfroi, S., Ottaviani, E., Testoni, N., Clvio, M., Cenacchi, A., Gamberi, B., Carrara, P., Gobbi, M. and Tun, S. (1994) "FLAG (fludarabine + high-dose cyiarabinc + G-CSF): an effective and tolerable protocol for the treatment of poor risk acute myeloid leukemias'1. Leukemia 8. 1842-1846.
  • Vogtlr, W.R. (1993) "High-dose carboplatin in (he treatment of hematologie malignancies". Oncology 50,42-46.
  • Wahlin, A. (1989) "Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia". Medical Oncology and Tumor Phamacotherapyv 6. 199-205.
  • Walters, R.S., Kantarjian, H.M., Keating, M.,J., Plunkcit, W.K., Estcy, E.H., Andersson, B., Beran, M., McCredie, K.B. and Freireich, E.J. (1988) "Miioxantronc and high-dose cytosine urabinaside in refractory acute myelngenous leukemia". Cancer 62,677-682.
  • Watson, A.M., Seymour, J., Lee, N., Whiteside, M. and Firkin, F. (1994) "An effective age-unrestricted m-AMSA-based second-line regimen for poor prognosis acute myeloid leukaemia". European Journal of Haematology 52, 80-86.
  • Wielenga, J.J., Vdlenga, E., Groenewegen, A., Sonneveld, P. and Lowenberg, B. (1996) "Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase Ml study", Leukemia 10.43-47.
  • Willemze, R., Archimbaud, E. and Muus, P. (1993) -Preliminary results with 5-aza-2'-deoxycyiidine (DAC)-containing chemotherapy in patients with relapsed or refractory acme leukemia. The EORTC Leukemia Cooperative Croup". leukemia 7, 49-50.
  • Willernze, R., Suciu, S., Archimbaud, E., Muus, P., Stryckmans, P., Louwagie, E.A., Berneman, Z., Tjean, M., Wijennans, P., Dohner, H., Jehn, U., Labar, B., Jaksic, B., Dardenne, M. and Zitloun, K. r 1997) "A randomized phase Il study on the effects of 5-aza-2'-deuxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase IT. study (06893)". Leukemia 11. S24-S27.
  • Yamada, K., Furusawa, S., Saito, K., Waga, K., Koike, T., Arimura, H., Aoyagi, A., Yamato, H., Sakuma, H. and Tsunogake, S. (1995) "Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenoux leukemia: a pilot study", leukemia 9, 10-14.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.